Therefore, in the HER2-low as well as HER2-positive, highly heterogeneous breast cancers might be responsive to the treatment of T-DXd that exhibited potent therapeutic efficacy through the delivery of a cytotoxic payload. This evidence concerns the gene ERBB2 and breast cancer.